

## Structure of a Fluorescent Compound Formed from 4-Hydroxy-2-nonenal and *N*<sup>ε</sup>-Hippuryllysine: A Model for Fluorophores Derived from Protein Modifications by Lipid Peroxidation


Koichi Itakura,<sup>\*,†</sup> Toshihiko Osawa,<sup>‡</sup> and Koji Uchida<sup>‡</sup>

Faculty of Education, Aichi University of Education, Kariya 448, Japan, and Laboratory of Food and Biodynamics, School of Agricultural Sciences, Nagoya University, Nagoya 464-01, Japan

Received July 8, 1997

### Introduction

It is well established that modification of proteins by lipid peroxidation produces fluorescence.<sup>1</sup> Because of the high sensitivity, this fluorescence is regarded as a good parameter for assessing oxidative damages in biological systems. Lipid peroxidation results in a variety of reactive aldehydes that are capable of covalently attaching to proteins.<sup>2</sup> There is increasing evidence that some of the aldehydes can produce fluorescent proteins.<sup>3–10</sup> 4-Hydroxy-2-nonenal (HNE, **1**) is a major lipid peroxidation-derived aldehyde that readily reacts with proteins under physiological conditions. Protein modifications by **1** have been implicated in various pathophysiological conditions such as atherosclerosis,<sup>11,12</sup> nephropathy,<sup>13</sup> Parkinson's disease,<sup>14</sup> and Alzheimer's disease.<sup>15</sup> It has been proposed that **1** contributes to the formation of fluorescent proteins during the lipid peroxidation of biological materials. For example, low-density lipoprotein (LDL) treated with **1** in vitro develops a protein fluorescence with an excitation maximum at 360 nm and an emission maximum at 430 nm, which agrees well with that observed in oxidized



**Figure 1.** HPLC analysis of fluorescent products formed by the reaction of **1** with **2** after 7 days. Fluorescence detection was carried out at 360 nm (excitation) and 430 nm (emission). The reaction and HPLC conditions are described in the Experimental Section.

LDL.<sup>16</sup> Although it is generally accepted that the fluorescence in HNE-treated proteins involves the modification of lysine residues, the structure of the fluorophore has so far not been determined. Therefore, we studied the reaction of **1** with the lysine-containing dipeptide, *N*<sup>ε</sup>-hippuryllysine (*N*<sup>ε</sup>-benzoyl-glycyl-L-lysine, BGL, **2**), at neutral pH. We report here the first structural characterization of an HNE-derived fluorescent compound **3**, a proposed model for fluorophores formed in protein during lipid peroxidation.

### Results and Discussion

A reaction mixture (6.0 mL) of **1** (10 mM) and **2** (100 mM) in 0.1 M phosphate buffer (pH 7.4) was incubated at room temperature for 7 days. HPLC analysis of the mixture revealed a major peak eluting at 29.7 min (Figure 1). To permit its structural analysis, the same reaction was carried out on a large scale. Purifications by Amberlite XAD-2 and then by repeated reversed-phase HPLC afforded a fluorescent compound **3** that had an excitation maximum at 362 nm and an emission maximum at 436 nm in ca. 100:1 H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (pH 2.7). It should be mentioned here that **3** is unstable in water. Fortunately, however, we found that it is quite stable in aqueous acetic acid. The mechanism by which acetic acid stabilizes **3** remains unclear. On the basis of NMR spectroscopy [<sup>1</sup>H, <sup>13</sup>C, DEPT, <sup>1</sup>H–<sup>1</sup>H COSY, HMQC, and HMBC (10 Hz)] and FAB mass spectrometry, the structure of **3** was confirmed as shown in Scheme 1. The FAB mass spectrum of **3** showed a pseudomolecular ion peak at *m/z* 749 (*M* + *H*)<sup>+</sup>, suggesting that **3** was composed of one molecule of **1** and two molecules of **2**. Table 1 shows selected <sup>13</sup>C and <sup>1</sup>H NMR data for **3**. The <sup>1</sup>H NMR

\* To whom correspondence should be addressed. Tel.: 0566-26-2596. Fax: 0566-26-2510. E-mail: kitakura@aecc.aichi-edu.ac.jp.

<sup>†</sup> Aichi University of Education.

<sup>‡</sup> Nagoya University.

(1) Kikugawa, K.; Beppu, M. *Chem. Phys. Lipids* **1987**, *44*, 277–296.

(2) Esterbauer, H.; Schaur, R. J.; Zollner, H. *Free Radical Biol. Med.* **1991**, *11*, 81–128.

(3) Chio, K. S.; Tappel, A. L. *Biochemistry* **1969**, *8*, 2821–2827.

(4) Chio, K. S.; Tappel, A. L. *Biochemistry* **1969**, *8*, 2827–2832.

(5) Kikugawa, K.; Ido, Y.; Mikami, A. *J. Am. Oil Chem. Soc.* **1984**, *61*, 1574–1581.

(6) Nair, V.; Offerman, R. J.; Turner, G. A.; Pryor, A. N.; Baenziger, N. C. *Tetrahedron* **1988**, *44*, 2793–2803.

(7) Itakura, K.; Uchida, K.; Osawa, T. *Chem. Phys. Lipids* **1996**, *84*, 75–79.

(8) Napetschnig, S.; Schauenstein, E.; Esterbauer, H. *Chem.-Biol. Interact.* **1988**, *68*, 165–177.

(9) Alaiz, M.; Barragán, S. *Chem. Phys. Lipids* **1995**, *77*, 217–223.

(10) Chen, P.; Wiesler, D.; Chmelik, J.; Novotny, M. *Chem. Res. Toxicol.* **1996**, *9*, 970–979.

(11) Steinberg, D.; Parthasarathy, S.; Carew, T. E.; Khoo, J. C.; Witztum, J. L. *N. Engl. J. Med.* **1989**, *320*, 915–924.

(12) Uchida, K.; Itakura, K.; Kawakishi, S.; Hiai, H.; Toyokuni, S.; Stadtman, E. R. *Arch. Biochem. Biophys.* **1995**, *324*, 241–248.

(13) Toyokuni, S.; Uchida, K.; Okamoto, K.; Hattori-Nakakuki, Y.; Hiai, H.; Stadtman, E. R. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 2616–2620.

(14) Yoritaka, A.; Hattori, N.; Uchida, K.; Tanaka, M.; Stadtman, E. R.; Mizuno, M. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 2696–2701.

(15) Montine, K. S.; Olson, S. J.; Amarnath, V.; Whetsell, W. O., Jr.; Graham, D. G.; Montine, T. J. *Am. J. Pathol.* **1997**, *150*, 437–443.

(16) Esterbauer, H.; Dieber-Rotheneder, M.; Waeg, G.; Striegl, G.; Jurgens, G. *Chem. Res. Toxicol.* **1990**, *3*, 77–92.



able. Analytical and preparative HPLC were carried out on a C18 reversed-phase column (5  $\mu$ m particle size, 8.0  $\times$  250 mm) at a flow rate of 2.0 mL/min. Products were monitored with a fluorescence detector at 360 nm (excitation) and 430 nm (emission). The concentration of Amberlite XAD-2 and HPLC eluents to dryness caused insolubilization of **3** in all solvents. Moreover, removal of acetic acid from the eluents by evaporation caused the decomposition of **3**. For these reasons, **3** was always treated as a water solution containing a small amount of acetic acid during its preparation and spectral measurements.

**Reaction of 1 with 2.** The reaction mixture (6.0 mL) containing **1** (10 mM) and **2** (100 mM) in 0.1 M phosphate buffer (pH 7.4) was allowed to stand at room temperature. After 7 days, the mixture was directly subjected to analytical HPLC; elution was with H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (100:1) containing 0–50% CH<sub>3</sub>CN, linear gradient over 40 min. Its HPLC profile is shown in Figure 1.

**Preparation of 3.** A solution (220 mL) of **1** (354 mg, 2.27 mmol) and **2** (6.76 g, 22.0 mmol) in 0.1 M phosphate buffer (pH 7.4) was allowed to stand at room temperature for 21 days. After the pH was adjusted to 5 with CH<sub>3</sub>CO<sub>2</sub>H, the solution was applied on an Amberlite XAD-2 column (2.5  $\times$  25.5 cm) equilibrated with H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (100:1). The column was eluted stepwise with H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (100:1), 20%, 40%, 60%, and 80% CH<sub>3</sub>OH/H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (100:1), and CH<sub>3</sub>OH (200 mL each). The fractions eluted with 60% and 80% CH<sub>3</sub>OH/H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (100:1) were combined and concentrated. The concentrated solution was subjected to preparative HPLC; elution was with H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (100:1) containing 0–45% CH<sub>3</sub>CN, linear gradient over 36 min. The HPLC fraction eluted at 29.2 min was collected and concentrated. The concentrated solution was again subjected to preparative HPLC; elution was with H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (100:1) containing 0–70% CH<sub>3</sub>OH, linear gradient over 50 min. The HPLC fraction eluted at 45.4 min was collected and concentrated. The concentrated solution was further subjected

to HPLC purification; elution was with H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H (100:1) containing 0–49% CH<sub>3</sub>CN–CH<sub>3</sub>OH (1:1), linear gradient over 87 min. The HPLC fraction eluted at 78.4 min was collected, and concentration of the combined fraction afforded **3** as a mixture (ca. 1:1) of two diastereomers (1.1 mg, 0.063% yield based on starting **1**). No attempt was made to separate the diastereomers. The yield of **3** was determined by measuring the released glycine from the acid hydrolysis of **3** (6 N HCl, 105 °C, 24 h): UV (ca. 100:1 H<sub>2</sub>O–CH<sub>3</sub>CO<sub>2</sub>H, pH 2.7)  $\lambda_{\text{max}}$  ( $\epsilon$ ) 361 nm ( $1.5 \times 10^4$ ); <sup>13</sup>C NMR (100 MHz; D<sub>2</sub>O; CH<sub>3</sub>CO<sub>2</sub>D as  $\delta$  21.10)  $\delta$  13.69, 21.49, 22.14, 22.77, 22.81, 22.96, 23.06, 27.72, 27.80, 28.12, 28.15, 30.88, 31.23, 31.29, 31.32, 35.89, 43.72, 43.77, 44.52, 44.57, 45.71, 54.20, 88.54, 95.89, 127.84, 129.47, 133.15, 133.39, 167.20, 171.63, 171.74, 171.77, 171.82, 177.33, 177.84, 177.93 (although each diastereomer has 39 carbons, the <sup>13</sup>C NMR spectrum showed only 36 signals probably because of signal overlapping); <sup>1</sup>H NMR (400 MHz; D<sub>2</sub>O; HOD as  $\delta$  4.80)  $\delta$  0.83 (3H, t,  $J = 6.7$  Hz), 0.77–0.94 (2H, m), 1.17–1.29 (4H, m), 1.34–1.48 (4H, m), 1.59–1.99 (9H, m), 2.01–2.09 (1H, m), 3.29–3.41 (2H, m), 3.42–3.50 (2H, m), 4.08–4.22 (4H, m), 4.32–4.40 (2H, m), 5.37 (<sup>1</sup>/<sub>2</sub>H, d,  $J = 3.1$  Hz), 5.38 (<sup>1</sup>/<sub>2</sub>H, d,  $J = 3.1$  Hz), 7.55–7.89 (10H, m), 8.08 (<sup>1</sup>/<sub>2</sub>H, d,  $J = 3.1$  Hz), 8.10 (<sup>1</sup>/<sub>2</sub>H, d,  $J = 3.1$  Hz); FABMS (glycerol)  $m/z$  749 (M + H)<sup>+</sup>, 733 (M + H – 16)<sup>+</sup>; HRFABMS (3-nitrobenzyl alcohol + poly(ethylene glycol)) calcd for C<sub>39</sub>H<sub>53</sub>O<sub>9</sub>N<sub>6</sub> 749.3874, found  $m/z$  749.3879 (M + H)<sup>+</sup>.

**Supporting Information Available:** <sup>1</sup>H NMR, <sup>13</sup>C NMR, DEPT (90° and 135°), <sup>1</sup>H–<sup>1</sup>H COSY, HMQC, HMBC, and FAB mass spectra of **3** (8 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

JO971239+